Latest from Baylor Cancer

Joyce A. O'Shaughnessy, MD, Texas Oncology-Baylor Charles A. Sammons Cancer Center, discusses insights from adding phosphoprotein testing to genomic testing for patients with breast cancer.
Joyce A. O'Shaughnessy, MD, Texas Oncology-Baylor Charles A. Sammons Cancer Center, discusses what recent research has shown regarding phosphoprotein assays in treatment decision-making for patients with breast cancer.
One promising avenue of exploration of biomarkers in AML is the Krebs cycle, where inhibiting a key metabolic enzyme has proved beneficial in early clinical studies.
Baylor Research Institute (BRI) at Dallas and the Translational Genomics Research Institute in Phoenix, AZ, today announce an agreement that will focus on accelerating early detection and treatments for patients with a broad range of cancers.
Alan M. Miller, MD, PhD, Director of the Baylor Charles A. Sammons Cancer Center and Chief of Oncology for the Baylor Health Care System discusses the benefits of liquid biopsy.
Daniel Von Hoff, MD, the Physician-in-Chief and Director of Translational Research at the Translational Genomics Research Institute (TGen) and a special consult with Baylor University College of Medicine, discuses combination treatments for pancreatic cancer.
Thomas E. Hutson, DO, PharmD, medical oncologist, Director of Genito-Urinary at Texas Oncology–Baylor Charles A. Sammons Cancer Center, discusses drug sequencing for the treatment of renal cell carcinoma.
M. Yair Levy, MD, discussed the impact of non-chemotherapeutic agents on the treatment of patients with NHL in an interview with OncLive.
Publication Bottom Border
Border Publication
x